Amgen And Novartis Partner With Karamo Brown To Support And Empower People Living With Migraine

IndustryPRwire -- Amgen announced a partnership with Karamo Brown, Emmy-nominated host from Netflix's hit show "Queer Eye," to support and empower people living with migraine. Karamo, who is known for helping people open up about themselves, is discussing his own struggles with migraine for the first time to help spread knowledge and acceptance. The Know Migraine Mission is a national effort by the companies behind Aimovig® (erenumab-aooe) to challenge public misconceptions, start new conversations and make the world a more migraine-friendly place. As part of the initiative, Karamo, who is not an Aimovig® patient but has dealt with migraine for years, will share his thoughts with people personally affected by migraine along with their friends, families and coworkers to help increase understanding of the disease.

Karamo Brown Commented "We've all been feeling the stress of this year, and it's compounded if you live with migraine like me. However, some people don't realize how challenging this disease can be, which is why I'm excited to lend my voice to the Know Migraine Mission, For people with migraine, talking about it can help make a real difference in their lives. Those conversations are important, even though they might look different today – so, whether it's a social-distanced lunch date with a friend or a video call with a doctor, it's important to take control where possible."

Migraine is a complex neurological disease that impacts millions of people in the U.S. Despite its prevalence and severity, migraine is often misunderstood and dismissed as being "just a headache." Research shows people may often feel stigmatized for missing time with friends, family and co-workers because of their migraine.

Karamo has struggled with migraine since he was in high school. The disease has impacted many parts of his life, including his ability to spend time with his two sons and other family and friends. As part of this partnership, Karamo is answering questions and sharing his thoughts with others who are living with this disease. On and social media, including the Aimovig Facebook and Instagram pages, Karamo will address how others can start new conversations to help reduce the stigma around migraine.

Aimovig, co-marketed in the U.S. by Amgen and Novartis, is the first Food and Drug Administration (FDA)-approved treatment indicated to prevent migraine in adults by targeting the calcitonin gene-related peptide (CGRP) receptor. Clinical study results have established the efficacy and safety profile of Aimovig across a spectrum of people living with both episodic and chronic migraine.

Darryl Sleep, M.D., senior vice president, Global Medical, and chief medical officer at Amgen Commented "Aimovig is proven to reduce monthly migraine days and for some, can cut the number of monthly migraine days in half or more, allowing patients to be there more in their everyday lives, But while treatment has evolved, progress still needs to be made to change the conversation around migraine and better support people living with this debilitating disease. Through the Know Migraine Mission, we want to educate the broader community about the impact of migraine and empower people to speak up about their disease and seek treatment options that may be appropriate for them."

Related Posts

Subscribe Our Newsletter